At 90 days, a strong trend toward decreased major adverse events was observed in the Impella 2.5-supported patients compared with that in the IABP group.
← all excerpts
Mechanical Circulatory Support for Acute Heart Failure Complicated by Cardiogenic Shock.
1
—
—